These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2834988)

  • 1. [Assay of decarboxy-prothrombin: its value in the diagnosis of hepatocellular carcinoma].
    Soulier JP; Lefrère JJ; Gozin D
    Ann Med Interne (Paris); 1988; 139(1):7-11. PubMed ID: 2834988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of plasma abnormal prothrombin (des-gamma-carboxy prothrombin) in hepatobiliary malignancies and other diseases.
    Nakao A; Suzuki Y; Isshiki K; Kimura Y; Takeda S; Kishimoto W; Nonami T; Harada A; Takagi H
    Am J Gastroenterol; 1991 Jan; 86(1):62-6. PubMed ID: 1702578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
    Soga K; Watanabe T; Aikawa K; Toshima M; Shibasaki K; Aoyagi Y
    Hepatogastroenterology; 1998; 45(23):1737-41. PubMed ID: 9840138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma.
    Nakao A; Taniguchi K; Inoue S; Harada A; Nonami T; Watanabe K; Takagi H
    Semin Surg Oncol; 1996; 12(3):160-3. PubMed ID: 8727604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases.
    Lamerz R; Runge M; Stieber P; Meissner E
    Anticancer Res; 1999; 19(4A):2489-93. PubMed ID: 10470180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coagulation assays as diagnostic markers of hepatocellular carcinoma.
    Lefrère JJ; Conard J; Mavier P; Bettan L; Beaugrand M; Gozin D; Lerable J; Dhumeaux D; Samama M
    Thromb Haemost; 1988 Dec; 60(3):468-70. PubMed ID: 2467402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assay of des-gamma-carboxyprothrombin using staphylocoagulase. Application to the diagnosis of cellular hepatocarcinoma.
    Soulier JP; Gozin D; Lefrère JJ
    Haematologia (Budap); 1986; 19(1):3-12. PubMed ID: 2424813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
    Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
    Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Surgical therapy of hepatic fibrolamellar carcinoma].
    Meriggi F; Forni E
    Ann Ital Chir; 2007; 78(1):53-8. PubMed ID: 17518332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acarboxy prothrombin (PIVKA II) as a tumour marker for hepatocellular carcinoma and other liver diseases.
    Mohamedein A; Yousif-Kadaru AG; Ahmed SA; Saida H; Zaki ZA; Eldin ; Fedail SS
    East Afr Med J; 1995 Sep; 72(9):584-7. PubMed ID: 7498046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
    Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
    Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.
    Nakamura S; Nouso K; Sakaguchi K; Ito YM; Ohashi Y; Kobayashi Y; Toshikuni N; Tanaka H; Miyake Y; Matsumoto E; Shiratori Y
    Am J Gastroenterol; 2006 Sep; 101(9):2038-43. PubMed ID: 16848811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal prothrombin (PIVKA-II) and hepatocellular carcinoma.
    Okuda H; Nakanish T; Furukawa M; Yamagata H; Obata H
    Trop Gastroenterol; 1991; 12(2):59-66. PubMed ID: 1719681
    [No Abstract]   [Full Text] [Related]  

  • 14. [Decarboxyprothrombin: importance in the diagnosis of hepatocellular carcinoma].
    Bon C; Brillard B; Gelineau MC; Mailliavin A; Trépo C; Pichot J
    Ann Biol Clin (Paris); 1998; 56(2):175-81. PubMed ID: 9754243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin.
    Dohmen K; Shigematsu H; Irie K; Ishibashi H
    Hepatogastroenterology; 2003; 50(54):2072-8. PubMed ID: 14696467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Watanabe K; Magario N; Yokoo T; Naraki T
    Cancer; 1999 Feb; 85(4):812-8. PubMed ID: 10091758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
    Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
    Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
    Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma.
    Beneduce L; Pesce G; Gallotta A; Zampieri F; Biasiolo A; Tono N; Boscato N; Gatta A; Pontisso P; Fassina G
    Eur J Clin Invest; 2008 Aug; 38(8):571-7. PubMed ID: 18625005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
    Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.